Table 5.
The baseline characteristics of training and validation set
| Characteristic | All patients (N = 1160) Number (%) |
Traning set (N = 570, 49.1%) Number (%) |
Validation set (N = 590, 50.9%) Number (%) |
p value |
|---|---|---|---|---|
| Age (years) | 0.349 | |||
| ≤ 10 | 242 (20.9%) | 117 (20.5%) | 125 (21.2%) | |
| 11–20 | 571 (49.2%) | 288 (50.5%) | 283 (48.0%) | |
| 21–30 | 206 (17.8%) | 105 (18.4%) | 101 (17.1%) | |
| 31–49 | 101 (8.7%) | 46 (8.1%) | 55 (9.3%) | |
| ≥ 50 | 40 (3.4%) | 14 (2.5%) | 26 (4.4%) | |
| Gender | 0.084 | |||
| Male | 733 (63.2%) | 346 (60.7%) | 387 (65.6%) | |
| Female | 427 (36.8%) | 224 (39.3%) | 203 (34.4%) | |
| Race | 0.727 | |||
| White | 1041 (89.7%) | 511 (89.6%) | 530 (89.8%) | |
| Black | 30 (2.6%) | 13 (2.3%) | 17 (2.9%) | |
| Other | 89 (7.7%) | 46 (8.1%) | 43 (7.3%) | |
| Primary site | 0.384 | |||
| Limb | 519 (44.7%) | 254 (44.6%) | 265 (44.9%) | |
| Cranial | 66 (5.7%) | 32 (5.6%) | 34 (5.8%) | |
| Spine | 88 (7.6%) | 37 (6.5%) | 51 (8.6%) | |
| Thoracic | 173 (14.9%) | 95 (16.7%) | 78 (13.2%) | |
| Pelvic | 314 (27.1%) | 152 (26.7%) | 162 (27.5%) | |
| Tumor size (cm) | 0.296 | |||
| < 5 | 221 (19.1%) | 119 (20.9%) | 102 (17.3%) | |
| 5–8 | 371 (32.0%) | 179 (31.4%) | 192 (32.5%) | |
| > 8 | 568 (49.0%) | 272 (47.7%) | 296 (50.2%) | |
| Tumor extent | 0.985 | |||
| Localized | 311 (26.8%) | 153 (26.8%) | 158 (26.8%) | |
| Regional | 533 (45.9%) | 263 (46.1%) | 270 (45.8%) | |
| Metastatic | 316 (27.2%) | 154 (27.0%) | 162 (27.5%) | |
| Cancer-directed surgery | 0.651 | |||
| No | 390 (33.6%) | 188 (33.0%) | 202 (34.2%) | |
| Yes | 770 (66.4%) | 382 (67.0%) | 388 (65.8%) | |
| Radiation | 0.636 | |||
| No | 584 (50.3%) | 291 (51.1%) | 293 (49.7%) | |
| Yes | 576 (49.7%) | 279 (48.9%) | 297 (50.3%) | |
| Chemotherapy | 0.032* | |||
| No | 40 (3.4%) | 13 (2.3%) | 27 (4.6%) | |
| Yes | 1120 (96.6%) | 557 (97.7%) | 563 (95.4%) | |
p value < 0.05*